Molecular Insight was subsequently acquired by Progenics in 2013, who oversaw the completion of clinical testing and development of the drug. Unlike LSA-MIBG, HSA-MIBG was subjected to the ...
“The LSA lets us demonstrate that we are generating that diversity.” The demand for new antibody drugs is expected to continue to grow, including therapies for diseases such as COVID-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback